WebCHEK2 gene (c.1283C>T) as well as a variant of uncer-tain clinical significance in the BLM gene (c.696C>A). This patient illustrates the need for AJ population screen-ing to include more than just the BRCA1 and BRCA2 AJ founder mutations. Had this patient only pursued the tradi-tional BRCA1/2 AJ founder mutations she may not have WebGTBC336 ATM/CHEK2 c.4002_4004delinsTTGCAGATTG (p.Leu1335Cysfs*6) / c.1100delC (p.Thr367Metfs*15) F breast cancer moderate+moderate YES PARPi (Off-Label) ... GTBC048 BLM/CHEK2 c.1642C>T p.Gln548*/c.1283C>T p.Ser428Phe F breast cancer moderate+unknown YES PARPi (Off-Label) GTBC130 BRCA1 c.(?_-19)_ ...
NM_007194.4(CHEK2):c.1283C>T (p.Ser428Phe) AND …
WebFeb 16, 2024 · This patient had a CHEK2 c.1283C>T gene mutation, which in a large case control study of Ashkenazi Jewish women was found to have a two-fold increased risk of breast cancer (OR=2.13, 95% CI, 1.26-3.69, P = .004). 29 This specific gene mutation is very rare outside of the Ashkenazi Jewish population. 29 Lumpectomy as opposed to … WebWant to learn more about who submits to ClinVar? Read information about groups that submit to ClinVar See the list of submitters with the number of records each has … tps group buffalo ny
Complexities of Variant Classification in Clinical …
WebApr 18, 2024 · CHEK2 missense variants are associated with relative risk for BC or CRC of less than 2 . The CHEK2 c.1283C>T; p.S428F is a known Ashkenazi founder variant reported at rates of ~ 3% among unselected AJ BC patients [10, 23]. It was detected in 2% of AJ BC patients in our cohort, a rate similar to that of BC patients and of other … WebJul 14, 2024 · Your cancer risk may be different depending on the specific CHEK2 mutation you have. Most CHEK2 mutations increase your risk for breast cancer. Some of the most … WebClinVar archives and aggregates information about relationships among variation and human health. An official website of the United States government. ... NM_007194.4(CHEK2):c.1283C>T (p.Ser428Phe) AND CHEK2-Related Cancer Susceptibility. Clinical significance: Pathogenic (Last evaluated: Sep 5, 2024) tpsh35-10